Bone Marrow Transplantation and Cellular Therapy Fellowship
A fellowship in bone marrow transplantation and cellular therapy is offered to individuals who have completed a fellowship in pediatric hematology-oncology.
Related Articles
Researchers turn back the clock on cancer cells to offer new treatment paradigm
Rhabdoid tumor cells were reverted from a cancerous state to normal. Discover how deletion of quality control protein DCAF5 may treat an undruggable cancer.
Tandem Thursday Breakfast Symposium: The Evolving Paradigm of Sickle Cell Disease Management
The paradigm of sickle cell disease management is rapidly evolving with exciting new advances in transplant and genetic therapies. Are you ready for these changes?…
Updated genomic landscape for pediatric acute myeloid leukemia enables new treatment possibilities
Scientists at St. Jude Children’s Research Hospital refined and enhanced the classification system for a type of pediatric leukemia using genomic and transcriptomic analysis.
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.